Results 61 to 70 of about 32,756 (253)

Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection

open access: yesFrontiers in Medicine
Endothelial dysfunction represents the critical pathophysiological mediator linking the modern epidemics of obesity, type 2 diabetes mellitus, and cardiovascular disease.
Allegra Battistoni   +5 more
doaj   +1 more source

Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists

open access: yesEndocrinology Research and Practice, 2022
Glucagon-like peptide-1 is the most potent incretin secreted from the intestinal tract. It is synthesized by L-cells in the jejunum and distal ileum of the gastrointestinal system.
Dilek Tüzün
doaj  

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update [PDF]

open access: yesEndocrinology and Metabolism
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic ...
Agnieszka Jakubowska   +2 more
doaj   +1 more source

Policy Progress in Using Economic Policy Instruments to Improve Nutrition: Challenges and Opportunities

open access: yesHealth Economics, EarlyView.
ABSTRACT Economic policy can be a powerful instrument to influence food environments and support improved diets and health. Over the past 20 years, the use of fiscal policy to improve diets has increased dramatically. This paper reviews the trajectory of policy change, and explores the ways in which research has informed three different dimensions of ...
Anne Marie Thow
wiley   +1 more source

Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists

open access: yesJournal of the American College of Cardiology, 2019
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of incretin mimetics with multisystem cardiometabolic effects. Six GLP-1RAs are approved for improving glycemic control by the U.S. Food and Drug Administration (FDA).
Muthiah, Vaduganathan   +9 more
openaire   +2 more sources

Insulin Resistance: An Update on Biochemical and Pathophysiological Mechanisms and Impact on Various Diseases

open access: yesiNew Medicine, EarlyView.
ABSTRACT Insulin resistance is the biological phenomenon in which the human body's normal response to the metabolic hormone insulin is compromised. Insulin is a regulator of most of the essential metabolic steps in the body that control energy homoeostasis, so dysregulation leads to multiple diverse human diseases including, most prominently, Type 2 ...
Peter J. Little   +12 more
wiley   +1 more source

Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea

open access: yesObesity Science & Practice
Background and Aim Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists are well‐established therapies for obesity and type 2 diabetes mellitus (T2DM). Emerging evidence also suggests their potential role in managing obstructive sleep apnea (OSA).
Bei‐Bei Qian   +4 more
doaj   +1 more source

The Endothelial CXCR Family in Vascular Health and Disease

open access: yesiNew Medicine, EarlyView.
ABSTRACT Endothelial cells (ECs) form the dynamic interface between blood and tissue, serving as key regulators of vascular homeostasis, inflammation, and repair. Among the molecular systems governing endothelial behavior, the C‐X‐C motif chemokine receptor (CXCR) family—originally characterized in immunology for its roles in leukocyte trafficking and ...
Zhiming Wu   +4 more
wiley   +1 more source

Euglycemic Ketoacidosis After the Addition of Glucagon-Like Peptide-1 Receptor Agonist: A Case Report

open access: yesAnnals of Internal Medicine: Clinical Cases
Euglycemic diabetic ketoacidosis (euDKA) is an acute, life-threatening metabolic emergency. It has been associated with several factors, including sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Ernest Oji Kanu   +4 more
doaj   +1 more source

Standardized MRI‐Based Quantification of Epicardial Adipose Tissue Volume: Reproducibility and Agreement With Cardiac Computed Tomography

open access: yesJournal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Background Epicardial adipose tissue volume (EATV) is increasingly recognized as a cardiometabolic risk marker associated with adverse outcomes. The most established approach for EATV quantification is cardiac computed tomography (CT). MRI offers a radiation‐free alternative allowing simultaneous assessment of myocardial function and tissue ...
Judith Gronwald   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy